慢性阻塞性肺疾病生物制剂治疗的影像学终点
慢性阻塞性肺疾病(COPD)以急性加重为特征,部分患者为2型炎症内型且对抗炎治疗反应更佳。靶向2型炎症及上游警报素的生物制剂可减少急性加重、改善肺功能,但需要反映疾病修饰的临床试验终点。影像学指标如气道壁厚度、黏液栓和通气缺损百分比在生物制剂治疗后可改变,证据多来自哮喘试验,可外推至COPD。
要点
- COPD生物制剂治疗可采用影像学终点评估结构重塑改变。
- 气道壁厚度、黏液栓和通气缺损百分比是潜在可改变的影像指标。
- 影像学终点可能显著减少临床试验所需样本量。
核心结论
- 影像学指标如气道壁厚度、黏液栓和通气缺损百分比在生物制剂治疗后可改变,有潜力作为COPD临床试验终点并显著减少样本量需求。
研究设计与样本
- 综述性文章,检索范围与纳入文献原文未报告;证据基础主要来自哮喘试验,可外推至COPD。
关键影像表现/征象
- 气道壁厚度在生物制剂治疗后似乎可改变。
- 黏液栓在生物制剂治疗后似乎可改变。
- 通气缺损百分比在生物制剂治疗后似乎可改变。
临床应用与阅片要点
- 作者认为影像学终点有潜力显著减少测试生物制剂对COPD结构重塑影响的临床试验样本量需求。
- 证据主要来自哮喘试验,可外推至COPD。
局限性
- 证据基础主要来自哮喘试验,而非COPD试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Chronic obstructive pulmonary disease (COPD) is a leading cause of respiratory morbidity and mortality. The disease is characterized by exacerbations, which result in high symptom burden and accelerated disease progression. A subset of patients exhibits a predominant type 2 inflammatory endotype, which is associated with increased risk of exacerbation and higher responsiveness to anti-inflammatory therapy. While biologics targeting type 2 inflammation and upstream alarmins have shown promise in reducing exacerbations and improving lung function, there is a need for clinical trial endpoints that reflect potential disease modification and enable an understanding of the mechanisms by which biologics may help patients with COPD. Measures of lung disease on imaging, including airway wall thickness, mucus plugging, and ventilation defect percentage, appear to be modifiable in response to therapy with biologics. The evidence base for treatment effects is derived largely from trials in asthma, but the findings can be extrapolated to COPD. Imaging endpoints have the potential to markedly decrease sample size requirements for clinical trials testing the effect of biologics on structural remodeling in COPD.
引用
- Chaudhary MFA, Bhatt SP. Imaging endpoints for biologic therapy in chronic obstructive pulmonary disease. Br J Radiol. 2026. PMID: 40742322. doi:10.1093/bjr/tqaf179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。